- Home
- FHTX vs RNAC Comparison
FHTX vs RNAC Comparison
Compare FHTX & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- RNAC
- Stock Information
- Founded
- FHTX 2015
- RNAC 2007
- Country
- FHTX United States
- RNAC United States
- Employees
- FHTX N/A
- RNAC N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- FHTX Health Care
- RNAC Health Care
- Exchange
- FHTX Nasdaq
- RNAC Nasdaq
- Market Cap
- FHTX 278.1M
- RNAC 316.1M
- IPO Year
- FHTX 2020
- RNAC 2016
- Fundamental
- Price
- FHTX $4.89
- RNAC $10.58
- Analyst Decision
- FHTX Strong Buy
- RNAC Strong Buy
- Analyst Count
- FHTX 8
- RNAC 4
- Target Price
- FHTX $12.63
- RNAC $40.00
- AVG Volume (30 Days)
- FHTX 118.7K
- RNAC 58.3K
- Earning Date
- FHTX 08-05-2025
- RNAC 08-07-2025
- Dividend Yield
- FHTX N/A
- RNAC N/A
- EPS Growth
- FHTX N/A
- RNAC N/A
- EPS
- FHTX N/A
- RNAC N/A
- Revenue
- FHTX $24,173,000.00
- RNAC $1,026,000.00
- Revenue This Year
- FHTX $33.60
- RNAC N/A
- Revenue Next Year
- FHTX $5.87
- RNAC N/A
- P/E Ratio
- FHTX N/A
- RNAC N/A
- Revenue Growth
- FHTX N/A
- RNAC 31.91
- 52 Week Low
- FHTX $2.95
- RNAC $8.46
- 52 Week High
- FHTX $10.25
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- FHTX 42.08
- RNAC 39.50
- Support Level
- FHTX $4.72
- RNAC $10.40
- Resistance Level
- FHTX $5.24
- RNAC $12.57
- Average True Range (ATR)
- FHTX 0.41
- RNAC 0.89
- MACD
- FHTX -0.16
- RNAC -0.35
- Stochastic Oscillator
- FHTX 13.73
- RNAC 10.22
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.